Location of Repository

Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C

By Patruno Savino FA, Capelli Anna, Maffezzini Elena, Brunetti Enrico, Zocchetti Cristina, Ciappina Valentina, Puoti Massimo, Sacchi Paolo, Bruno Raffaele, Malfitano Antonello and Filice Gaetano

Abstract

<p>Abstract</p> <p>Background</p> <p>The standard of care for HCV Hepatitis is the combination of interferon (IFN) plus Ribavirin. In HIV patients the use of this combination therapy may induce drug interactions, and reduces the adherence to HAART.</p> <p>The aim of this study is to evaluate safety and efficacy of a 48 weeks daily dose IFN schedule.</p> <p>Methods</p> <p>We evaluated 50 coinfected patients; alpha IFN 2a was administered at a dose of 3 MU daily. The baseline values were the following : CD4+ 515 cells/mmc (mean); HIV-RNA <50 copies/ml in all patients; HCV-RNA 28, 3 × 106 copies/ml.</p> <p>Results</p> <p>At 48 weeks, 10 patients (20%) achieved a biochemical and virological response according to an intention to treat analysis.</p> <p>Twenty four patients (48%) underwent a drop-out mainly by side effects related to overlapping toxicity of interferon and antiretroviral therapy. All the patients, who responded to the treatment, showed a fast relapse one month after the end of treatment.</p> <p>Conclusion</p> <p>Although our results demonstrated a very poor outcome and a bad tolerance to interferon monotherapy, this approach should not be dropped out, mainly in patients at high risk for side effects and in those with cirrhosis who do not tolerate or are at increased risk for the use of ribavirin.</p

Topics: HIV, HCV, Coinfection, Interferon, Ribavirin, Internal medicine, RC31-1245, Medicine, R, DOAJ:Internal medicine, DOAJ:Medicine (General), DOAJ:Health Sciences, Infectious and parasitic diseases, RC109-216
Publisher: BioMed Central
Year: 2002
DOI identifier: 10.1186/1471-2334-2-17
OAI identifier: oai:doaj.org/article:15f815647aad4e63bbec7ed83b5f7926
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1471-2334 (external link)
  • http://www.biomedcentral.com/1... (external link)
  • https://doaj.org/article/15f81... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.